Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
LMNX's Cash to Debt is ranked higher than
98% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.21 vs. LMNX: No Debt )
Ranked among companies with meaningful Cash to Debt only.
LMNX' s 10-Year Cash to Debt Range
Min: 3.96  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.90
LMNX's Equity to Asset is ranked higher than
94% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. LMNX: 0.90 )
Ranked among companies with meaningful Equity to Asset only.
LMNX' s 10-Year Equity to Asset Range
Min: 0.77  Med: 0.89 Max: 0.97
Current: 0.9
0.77
0.97
Interest Coverage No Debt
LMNX's Interest Coverage is ranked higher than
96% of the 108 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 53.79 vs. LMNX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
LMNX' s 10-Year Interest Coverage Range
Min: 5.66  Med: 10000.00 Max: 9999.99
Current: No Debt
5.66
9999.99
F-Score: 6
Z-Score: 14.51
M-Score: -2.89
WACC vs ROIC
2.63%
20.64%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 15.05
LMNX's Operating margin (%) is ranked higher than
76% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.56 vs. LMNX: 15.05 )
Ranked among companies with meaningful Operating margin (%) only.
LMNX' s 10-Year Operating margin (%) Range
Min: -1523.06  Med: -8.26 Max: 12.93
Current: 15.05
-1523.06
12.93
Net-margin (%) 16.61
LMNX's Net-margin (%) is ranked higher than
89% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.77 vs. LMNX: 16.61 )
Ranked among companies with meaningful Net-margin (%) only.
LMNX' s 10-Year Net-margin (%) Range
Min: -1449.74  Med: -3.61 Max: 17.2
Current: 16.61
-1449.74
17.2
ROE (%) 12.32
LMNX's ROE (%) is ranked higher than
69% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.29 vs. LMNX: 12.32 )
Ranked among companies with meaningful ROE (%) only.
LMNX' s 10-Year ROE (%) Range
Min: -90.69  Med: -0.70 Max: 13.24
Current: 12.32
-90.69
13.24
ROA (%) 11.10
LMNX's ROA (%) is ranked higher than
84% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.52 vs. LMNX: 11.10 )
Ranked among companies with meaningful ROA (%) only.
LMNX' s 10-Year ROA (%) Range
Min: -82.92  Med: -0.53 Max: 11.77
Current: 11.1
-82.92
11.77
ROC (Joel Greenblatt) (%) 31.88
LMNX's ROC (Joel Greenblatt) (%) is ranked higher than
76% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.56 vs. LMNX: 31.88 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
LMNX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -678.57  Med: -9.72 Max: 40.65
Current: 31.88
-678.57
40.65
Revenue Growth (3Y)(%) 7.50
LMNX's Revenue Growth (3Y)(%) is ranked higher than
66% of the 152 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. LMNX: 7.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
LMNX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 7.5  Med: 22.00 Max: 191.1
Current: 7.5
7.5
191.1
EBITDA Growth (3Y)(%) 5.60
LMNX's EBITDA Growth (3Y)(%) is ranked lower than
52% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.90 vs. LMNX: 5.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
LMNX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -69.3  Med: 8.20 Max: 45.3
Current: 5.6
-69.3
45.3
EPS Growth (3Y)(%) 39.90
LMNX's EPS Growth (3Y)(%) is ranked higher than
90% of the 127 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.70 vs. LMNX: 39.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
LMNX' s 10-Year EPS Growth (3Y)(%) Range
Min: -52.7  Med: 6.70 Max: 104.9
Current: 39.9
-52.7
104.9
» LMNX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

LMNX Guru Trades in Q3 2014

Joel Greenblatt 38,571 sh (New)
PRIMECAP Management 1,987,848 sh (-2.57%)
Paul Tudor Jones 16,667 sh (-35.21%)
Jim Simons 17,200 sh (-86.58%)
» More
Q4 2014

LMNX Guru Trades in Q4 2014

Jim Simons 109,200 sh (+534.88%)
Joel Greenblatt 96,646 sh (+150.57%)
Paul Tudor Jones 22,867 sh (+37.20%)
PRIMECAP Management 1,904,718 sh (-4.18%)
» More
Q1 2015

LMNX Guru Trades in Q1 2015

Jim Simons 305,900 sh (+180.13%)
Paul Tudor Jones 49,199 sh (+115.15%)
Joel Greenblatt Sold Out
PRIMECAP Management Sold Out
» More
Q2 2015

LMNX Guru Trades in Q2 2015

Chuck Royce 3,200 sh (New)
Jim Simons 537,715 sh (+75.78%)
Paul Tudor Jones 52,189 sh (+6.08%)
» More
» Details

Insider Trades

Latest Guru Trades with LMNX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 20.30
LMNX's P/E(ttm) is ranked higher than
71% of the 113 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.70 vs. LMNX: 20.30 )
Ranked among companies with meaningful P/E(ttm) only.
LMNX' s 10-Year P/E(ttm) Range
Min: 16.42  Med: 68.83 Max: 646.43
Current: 20.3
16.42
646.43
Forward P/E 34.84
LMNX's Forward P/E is ranked lower than
80% of the 75 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.41 vs. LMNX: 34.84 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 20.30
LMNX's PE(NRI) is ranked higher than
71% of the 112 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 28.80 vs. LMNX: 20.30 )
Ranked among companies with meaningful PE(NRI) only.
LMNX' s 10-Year PE(NRI) Range
Min: 16.42  Med: 69.52 Max: 603.33
Current: 20.3
16.42
603.33
P/B 2.34
LMNX's P/B is ranked higher than
59% of the 176 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.89 vs. LMNX: 2.34 )
Ranked among companies with meaningful P/B only.
LMNX' s 10-Year P/B Range
Min: 2.02  Med: 3.51 Max: 12.35
Current: 2.34
2.02
12.35
P/S 3.37
LMNX's P/S is ranked lower than
57% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.71 vs. LMNX: 3.37 )
Ranked among companies with meaningful P/S only.
LMNX' s 10-Year P/S Range
Min: 2.87  Med: 5.53 Max: 12.99
Current: 3.37
2.87
12.99
PFCF 21.98
LMNX's PFCF is ranked higher than
73% of the 82 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.91 vs. LMNX: 21.98 )
Ranked among companies with meaningful PFCF only.
LMNX' s 10-Year PFCF Range
Min: 20.06  Med: 60.98 Max: 451.73
Current: 21.98
20.06
451.73
POCF 13.19
LMNX's POCF is ranked higher than
68% of the 114 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.50 vs. LMNX: 13.19 )
Ranked among companies with meaningful POCF only.
LMNX' s 10-Year POCF Range
Min: 12.2  Med: 33.07 Max: 301.5
Current: 13.19
12.2
301.5
EV-to-EBIT 23.74
LMNX's EV-to-EBIT is ranked lower than
65% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.94 vs. LMNX: 23.74 )
Ranked among companies with meaningful EV-to-EBIT only.
LMNX' s 10-Year EV-to-EBIT Range
Min: -858.9  Med: 31.35 Max: 232.4
Current: 23.74
-858.9
232.4
PEG 0.91
LMNX's PEG is ranked higher than
88% of the 65 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.71 vs. LMNX: 0.91 )
Ranked among companies with meaningful PEG only.
LMNX' s 10-Year PEG Range
Min: 1.27  Med: 2.28 Max: 5.38
Current: 0.91
1.27
5.38
Shiller P/E 41.92
LMNX's Shiller P/E is ranked lower than
70% of the 80 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.01 vs. LMNX: 41.92 )
Ranked among companies with meaningful Shiller P/E only.
LMNX' s 10-Year Shiller P/E Range
Min: 36.65  Med: 95.41 Max: 386.75
Current: 41.92
36.65
386.75
Current Ratio 6.48
LMNX's Current Ratio is ranked higher than
88% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.42 vs. LMNX: 6.48 )
Ranked among companies with meaningful Current Ratio only.
LMNX' s 10-Year Current Ratio Range
Min: 2.39  Med: 8.31 Max: 59.71
Current: 6.48
2.39
59.71
Quick Ratio 5.38
LMNX's Quick Ratio is ranked higher than
89% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.60 vs. LMNX: 5.38 )
Ranked among companies with meaningful Quick Ratio only.
LMNX' s 10-Year Quick Ratio Range
Min: 1.86  Med: 7.17 Max: 58.8
Current: 5.38
1.86
58.8
Days Inventory 184.38
LMNX's Days Inventory is ranked lower than
75% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 128.59 vs. LMNX: 184.38 )
Ranked among companies with meaningful Days Inventory only.
LMNX' s 10-Year Days Inventory Range
Min: 69.92  Med: 137.17 Max: 274.18
Current: 184.38
69.92
274.18
Days Sales Outstanding 34.97
LMNX's Days Sales Outstanding is ranked higher than
88% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 62.83 vs. LMNX: 34.97 )
Ranked among companies with meaningful Days Sales Outstanding only.
LMNX' s 10-Year Days Sales Outstanding Range
Min: 38.52  Med: 58.60 Max: 153.06
Current: 34.97
38.52
153.06

Valuation & Return

vs
industry
vs
history
Price/Net Cash 9.23
LMNX's Price/Net Cash is ranked higher than
62% of the 42 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 12.92 vs. LMNX: 9.23 )
Ranked among companies with meaningful Price/Net Cash only.
LMNX' s 10-Year Price/Net Cash Range
Min: 3.74  Med: 10.87 Max: 135.16
Current: 9.23
3.74
135.16
Price/Net Current Asset Value 4.97
LMNX's Price/Net Current Asset Value is ranked higher than
67% of the 114 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.94 vs. LMNX: 4.97 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
LMNX' s 10-Year Price/Net Current Asset Value Range
Min: 2.85  Med: 7.15 Max: 40.76
Current: 4.97
2.85
40.76
Price/Tangible Book 3.41
LMNX's Price/Tangible Book is ranked higher than
60% of the 156 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.28 vs. LMNX: 3.41 )
Ranked among companies with meaningful Price/Tangible Book only.
LMNX' s 10-Year Price/Tangible Book Range
Min: 2.65  Med: 5.52 Max: 16.94
Current: 3.41
2.65
16.94
Price/Projected FCF 1.38
LMNX's Price/Projected FCF is ranked higher than
65% of the 95 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.73 vs. LMNX: 1.38 )
Ranked among companies with meaningful Price/Projected FCF only.
LMNX' s 10-Year Price/Projected FCF Range
Min: 1.29  Med: 2.91 Max: 11.52
Current: 1.38
1.29
11.52
Price/Median PS Value 0.61
LMNX's Price/Median PS Value is ranked higher than
85% of the 167 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.15 vs. LMNX: 0.61 )
Ranked among companies with meaningful Price/Median PS Value only.
LMNX' s 10-Year Price/Median PS Value Range
Min: 0.53  Med: 1.37 Max: 28.57
Current: 0.61
0.53
28.57
Price/Peter Lynch Fair Value 1.94
LMNX's Price/Peter Lynch Fair Value is ranked higher than
52% of the 48 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.99 vs. LMNX: 1.94 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
LMNX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 1.3  Med: 3.50 Max: 25.89
Current: 1.94
1.3
25.89
Price/Graham Number 1.75
LMNX's Price/Graham Number is ranked higher than
64% of the 90 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.52 vs. LMNX: 1.75 )
Ranked among companies with meaningful Price/Graham Number only.
LMNX' s 10-Year Price/Graham Number Range
Min: 1.5  Med: 4.23 Max: 15.42
Current: 1.75
1.5
15.42
Earnings Yield (Greenblatt) (%) 4.20
LMNX's Earnings Yield (Greenblatt) (%) is ranked higher than
58% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. LMNX: 4.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
LMNX' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.4  Med: 2.20 Max: 5.8
Current: 4.2
0.4
5.8
Forward Rate of Return (Yacktman) (%) 13.26
LMNX's Forward Rate of Return (Yacktman) (%) is ranked higher than
55% of the 92 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 12.01 vs. LMNX: 13.26 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
LMNX' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -53.6  Med: 0.50 Max: 32.4
Current: 13.26
-53.6
32.4

Analyst Estimate

Dec15 Dec16
Revenue(Mil) 235 251
EPS($) 0.64 0.53
EPS without NRI($) 0.64 0.53

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:LMX.Germany,
Luminex Corp was incorporated under the laws of the State of Texas in May 1995, and was reincorporated in the State of Delaware in July 2000. The Company develops, manufactures and sells proprietary biological testing technologies and products with applications throughout the life sciences and diagnostics industries. The Company has two reportable segments; TSP segment and ARP segment. The TSP segment represents the Company's base business and consists of system sales to partners, raw bead sales, royalties, service and support of the technology, and other miscellaneous items and the ARP segment is involved in the development and sale of assays on xMAP technology for use on Luminex's installed base of systems, as well as the sale of automated punching systems. The Company also develops and manufactures the proprietary xMAP laboratory instrumentation and the proprietary xMAP microspheres and sells them. The ARP segment is mainly involved in the development and sale of assays utilizing xMAP technology on its installed base of systems. The ARP segment is mainly focused on multiplexed applications for the human molecular clinical diagnostics market. The Company's diagnostic market competitors include Abbott Laboratories, Beckman Coulter, Inc., Celera Corporation, Cepheid, Johnson & Johnson, Roche Diagnostics, Siemens Medical, and Hologic, Inc. It currently owns 281 issued patents, including 110 issued patents in the United States. The Company's trademark includes Luminex, xMAP, xTAG, Luminex 100/200 MicroPlex, MAGPIX, MagPlex, SeroMAP, xPONENT, FlexmiR, NeoPlex4, LumAvidin Et cetera. The Company is subject to federal, state and local laws and regulations relating to the protection of human health and the environment.
» More Articles for LMNX

Headlines

Articles On GuruFocus.com
Atossa Genetics Subsidiary The NRLBH Now Provides Enhanced Pharmacogenetic Test Based on Luminex xTA Jul 22 2015 
BSX and ABMD Highlight Increased Insider Buying in the Medical Technology Sector May 14 2013 
Luminex Corp. (LMNX) CEO Patrick J Balthrop buys 7,000 Shares Mar 02 2010 
Luminex Corp. (LMNX) CEO Patrick J Balthrop buys 7,000 Shares Nov 16 2009 
Luminex Corporation Reports Second Quarter 2009 Results Aug 06 2009 
Luminex Corporation Reports Fourth Quarter and Year-End 2008 Results Feb 05 2009 
Luminex Corporation Fourth Quarter and Year End 2008 Earnings Release Scheduled for February 5, 2009 Jan 21 2009 

More From Other Websites
Luminex Corporation To Present At The 2015 Wedbush PacGrow Healthcare Conference Aug 26 2015
Luminex Corporation Submits 510(k) Application for the NxTAG® Respiratory Pathogen Panel Aug 26 2015
LUMINEX CORP Financials Aug 12 2015
10-Q for Luminex Corp. Aug 06 2015
Luminex Corporation Reports Record 2nd Quarter 2015 Results Aug 05 2015
Luminex Corporation To Present At The 2015 Wedbush PacGrow Healthcare Conference Aug 05 2015
Street Talk: VFC, LNKD, WLK, FL & LMNX Aug 04 2015
LUMINEX CORP Files SEC form 10-Q, Quarterly Report Aug 04 2015
Luminex (LMNX) Tops Q2 Earnings, Revenues; Pipeline Strong - Analyst Blog Aug 04 2015
Wedbush Analyst Upgrades Luminex After Quarterly Results, New CEO Aug 04 2015
Luminex upgraded by Wedbush Aug 04 2015
Edited Transcript of LMNX earnings conference call or presentation 3-Aug-15 8:30pm GMT Aug 04 2015
Luminex beats Street 2Q forecasts Aug 03 2015
Luminex beats Street 2Q forecasts Aug 03 2015
Luminex Corp Earnings Call scheduled for 4:30 pm ET today Aug 03 2015
Luminex Corporation Submits FDA 510(k) Submissions for ARIES™ System and ARIES™ HSV 1&2 Assay Aug 03 2015
LUMINEX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 03 2015
Luminex Corporation Reports Record 2nd Quarter 2015 Results Aug 03 2015
Q2 2015 Luminex Corp Earnings Release - After Market Close Aug 03 2015
Atossa Genetics Subsidiary The NRLBH Now Provides Enhanced Pharmacogenetic Test Based on Luminex... Jul 22 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK